Interleukin-6 in human multiple myeloma

Blood

Volumn 85, Issue 4, 1995, Pages 863-872

  Klein, Bernard ^a   Zhang, Xue Guang ^b   Lu, Zhao Yang ^b   Bataille, Régis ^b  

^a CNRS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; ESTROGEN; GLYCOPROTEIN GP 130; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

CELL PROLIFERATION; DRUG MECHANISM; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0028921477     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v85.4.863.bloodjournal854863     Document Type: Review

References (123)

1. Billadeau D, Ahmann G, Greipp P, Van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178:1023, 1993
2. Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J, Morley AA: Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene. Blood 82:202, 1993
3. Bakkus M, Heirman C, Van Riet I, Van Camp B, Thielemans K: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80:2326, 1992
4. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517, 1989
5. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198, 1991
6. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83, 1988
7. Banchereau J, Rousset F: Human B lymphocytes: Phenotype, proliferation and differentiation. Adv Immunol 52:125, 1992
8. Liu YJ, Johnson GD, Gordon J, Maclennan ICM: Germinal centres in T-cell-dependent antibody responses. Immunol Today 13:17, 1992
9. Kishimoto T, Taga T, Akira S: Cytokine signal transduction. Cell 76:253, 1994
10. MacMillan R, Longmire RL, Yelenosky R, Lang JE, Heath V, Craddock CG: Immunoglobulin synthesis by human lymphoid tissues: Normal bone marrow as a major site of IgG production. J Immunol 109:1386, 1972
11. Hibi T, Dosh HM: Limiting dilution analysis of the B cell compartment in human bone marrow. Eur J Immunol 16:139, 1986
12. Vernino L, McAnally LM, Ramberg J, Lipsky PE: Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J Immunol 148:404, 1992
13. Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89:1890, 1992
14. Werner Favre C, Gauchat JF, Mazzei G, Aubry JP, Bonnefoy JY, Zubler RH: Similar Cd40 ligand expression on El-4 thymoma cell lines with widely different helper activity for B lymphocytes. Immunology 81:111, 1994
15. Werner Favre C, Matthes T, Barnet M, Zubler RH: High IgE secretion capacity of human plasma cells. Eur J Immunol 23:2038, 1993
16. Nohoyama S, Hottenbaugh D, Aruffo A, Ledbetter JA, Ochs HD: B cell activation via CD40 is required for specific antibody production by antigen-stimulated B cells. J Exp Med 178:1097, 1993
17. Liu YJ, Cairns JA, Holder MJ, Abbot SD, Jansen KU, Bonnefoy JY, Gordon J, MacLennan IC: Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 21:1107, 1991
18. Brière F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J: Human interleukin-10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 179:757, 1994
19. Splawski JB, McAnally LM, Lipsky PE: IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol 144:562, 1990
20. Xia X, Lee HL, Clark SC, Choi YS: Recombinant interleukin (IL)2-induced human B cell differentiation is mediated by autocrine IL6. Eur J Immunol 19:2275, 1989
21. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T: Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490, 1985
22. Muraguchi A, Hirano T, Tang B, Matsuda T, Hori Y, Makajima K, Kishimoto T: The essential tole of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167:332, 1988
23. Raynal MC, Liu Z, Hirano T, Mayer L, Kishimoto K, Chen-Kiang S: Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. Proc Natl Acad Sci USA 86:8024, 1989
24. Tanner JE, Tosato G: Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 79:452, 1992
25. Levy Y, Fermand JP, Navarro S, Schmitt C, Vainchenker W, Seligmann M, Brouet JC: Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy. Proc Natl Acad Sci USA 87:3309, 1990
26. Levy Y, Labaume S, Gendron MC, Brouet JC: Modulation of spontaneous B-cell differentiation in macroglobulinemia by retinoic acid. Blood 83:2206, 1994
27. Jelinek DF, Lipsky PE: The role of B cell proliferation in the generation of immunoglobulin secreting cells in man. J Immunol 130:2597, 1983
28. Gavarotti P, Bacadoro M, Redoglia V, Golzio F, Pileri A: Reactive plasmacytosis: Case report and review of the literature. Acta Haematol 13:108, 1985
29. Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B: Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 33:398, 1990
30. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyasaki JI, Yamamura KI, Hirano T, Kishimoto T: IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86:7547, 1989
31. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 89:232, 1992
32. Roldan E, Rodriguez C, Navas G, Parra C, Brieva JA: Cytokine network regulating terminal maturation of human bone marrow B cells capable of spontaneous and high rate Ig secretion in vitro. J Immunol 149:2367, 1992
33. Roldan E, Garcia-Pardo A, Brieva JA: VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow capable of spontaneous and high rate immunoglobulin secretion. J Exp Med 175:1739, 1992
34. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Köhler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339, 1994
35. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561, 1994
36. Zhang XG, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74:11, 1989
37. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B: Granulocyte-macrophage colony stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 76:2599, 1990
38. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I: The role of interleukin-1 and tumor necrosis factor-α in human multiple myeloma. Br J Haematol 74:424, 1990
39. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Gugliemo R: Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380, 1989
40. Hermann F, Andreef M, Gruss HJ, Brach MA, Lübbert M, Mertelsmann R: Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 78:2070, 1991
41. Sonneveld P, Schoester M, de Leeuw K: In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Br J Haematol 79:589, 1991
42. Zhang XG, Bataille R, Widjenes J, Klein B: Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 69:1373, 1992
43. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA: Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
44. Nilsson K, Jernberg H, Pettersson M: IL-6 as a growth factor for human myeloma cells. A short overview. Curr Top Microbiol Immunol 166:3, 1990
45. Palumbo A, Battaglio S, Napoli P, Omede P, Fusaro A, Bruno B, Boccadoro M, Pileri A: Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 86:726, 1994
46. Drewinko B, Alexanian R: Growth kinetics of plasma cell myeloma. J Natl Cancer Inst 58:1247, 1977
47. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA: Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 62:969, 1987
48. Borinaga AM, Millar BC, Bell JB, Joffe JK, Millar JL, Gooding R, Riches P, McElwain TJ: Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro. Br J Haematol 76:476, 1990
49. Rhodes EG, Olive C, Flynn MP: A serum-free culture method for myeloma progenitors in vitro: Proliferative and immunophenotypic characteristics. Exp Hematol 18:79, 1990
50. Ballester OF, Moscinski LC, Lyman GH, Chaney JV, Saba HI, Spiers ASD, Klein C: High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83:1903, 1994
51. Lokhorst HM, Boom SE, Terpstra W, Roholl P, Gerdes J, Bast BJEG: Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol 69:477, 1988
52. Greil R, Fasching B, Loidl P, Huber H: Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: An in situ analysis. Blood 78:180, 1991
53. Tsuchiya H, Epstein J, Jelvanayagam P, Dedman JR, Galiick G, Alexanian R, Barlogie B: Correlated flow cytometry analysis of H-Ras p21 and nuclear DNA in multiple myeloma. Blood 72:796, 1988
54. Lokhorst HM, Boom SE, Bast BJEG, Peters PJ, Tedder TF, Gerdes J, Petersen E, Ballieux RE: Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern. J Clin Invest 79:1401, 1987
55. Bergui L, Schena M, Gaidano G, Riva M, Caligaris Cappio F: Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613, 1989
56. Tokumine Y, Nishimori Y, Shibayama H, Shibano M, Tagawa S, Machii T, Kitani T: Failure of IL-3 plus IL-6 to induce the proliferation and differentiation of malignant plasma cell precursors from peripheral blood in multiple myeloma (letter). Leukemia 7:333, 1993
57. Goto H, Shimazaki C, Ashihara E, Ohkawa K, Oku N, Inaba T, Murakami S, Fujita N, Nakagawa M: Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance. Acta Haematol 88:129, 1992
58. Sawamura M, Murakami H, Tamura J, Matsushima T, Sato S, Naruse T, Tsuchiya J: Tumour necrosis factor-α and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma. Br J Haematol 88:17, 1994
59. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
60. Shimizu S, Yoshioka R, Hirose Y, Susumu S, Tachibana J, Konda S: Establishment of two interleukin-6 (B cell stimulatory factor 2/interferonβ2) dependent human bone marrow-derived myeloma cell lines. J Exp Med 169:339, 1989
61. Tanabe O, Kawano M, Tanaka H, Iwato K, Asaoku H, Ishikawa H, Nobuyoshi M, Hiraao T, Kishimoto T, Kuramoto A: BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol 31:258, 1989
62. Salmon SE: Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 10:135, 1973
63. Hammerton K, Cooper DA, Duckett M, Penny R: Biosynthesis of immunoglobulins in human immunoproliferative diseases. I-Kinetics of synthesis and secretion of immunoglobulins and protein by bone marrow cells in myeloma. J Immunol 121:409, 1978
64. Cooper DA, Miller AC, Penny R: Biosynthesis of immunoglobulins in human immunoproliferative diseases. II-Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with throw calculated from clinical staging systems. Acta Haernatol 68:224, 1982
65. Iwato K, Kawano M, Asaoku H, Tanabe O, Tanaka H, Kuramoto A: Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood 72:562, 1988
66. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
67. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K: Human CD38: A glycoprotein in search of a function. Immunol Today 15:95, 1994
68. Aarden LA, de Groot ER, Schaap OL, Lansdorp PM: Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411, 1987
69. Chen-Kiang S, Hsu W, Hatkunam Y, Zhang X: Nuclear signalling by interleukin-6. Curr Opin Immunol 5:124, 1993
70. Levy Y, Tsapis A, Brouet JC: Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991
71. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP: Characterization of an interleukin-6-mediated autocrine loop in the human multiple myeloma cell line U266. Blood 77:587, 1991
72. Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Wijdenes J, Mannoni P, Maraninchi D, Piechaczyk M, Bataille R, Klein B: In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 21:1759, 1991
73. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712, 1993
74. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
75. Degrassi A, Hibert DM, Rudikoff S, Anderson AO, Potter M, Coon HG: In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 90:2060, 1993
76. Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson KC, Freedman AS, Griffin JD: Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol 143:3543, 1989
77. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
78. Reibnegger G, Krainer M, Herold M, Ludwig H, Watcher H, Huber H: Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51:6250, 1991
79. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B: High amounts of circulating interleukin-6 (IL-6) in the form of monomeric immune complexes during anti-IL-6 therapy. Toward a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22:2819, 1992
80. Montero-Julian FA, Klein B, Gautherot E, Brailly H: Pharmacokinetic study of anti-IL-6 therapy with monoclonal antibodies: Enhancement of IL-6 clearance by a cocktail of anti-IL-6 antibodies. Blood (in press)
81. Kishimoto T, Akira S, Taga T: Interleukin-6 and its receptor - A paradigm for cytokines. Science 258:593, 1992
82. Yasukawa K, Saito T, Fukunaga T, Sekimori Y, Koishihara Y, Fukui H, Ohsugi Y, Matsuda T, Yawata H, Hirano T, Taga T, Kishimoto T: Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biol Chem 108:673, 1990
83. Davis S, Aldrich TH, Ip NY, Stahl N, Scherer S, Farruggela T, DiStefano PS, Curtis R, Panayotatos N, Gascan H, Chevalier S, Yancopoulos GD: Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses. Science 259:1736, 1993
84. Mullberg J, Dittrich E, Graeve L, Gerhartz C, Yasukawa K, Taga T, Kishimoto T, Heinrich PC, Rosejohn S: Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett 332:174, 1993
85. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ: Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96, 1992
86. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23:820, 1993
87. Greipp PR, Gaillard JP, Kalish LA, Oken MM, Miller AM, Kyle RA, Klein B: Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern cooperative oncology group (ECOG) myeloma trial E9487. Proc Am Soc Clin Oncol 12:404, 1993 (abstr)
88. Castell JV, Geiger T, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC: Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 177:357, 1988
89. Suzuki H, Yasukawa K, Saito T, Narazaki M, Hasegawa A, Taga T, Kishimoto T: Serum soluble interleukin-6 receptor in MRL/ 1pr mice is elevated with age and mediates interleukin-6 signal. Eur J Immunol 23:1078, 1993
90. Yasukawa K, Futatsugi K, Saito T, Yawata H, Narazaki M, Suzuki H, Taga T, Kishimoto T: Association of recombinant soluble IL-6-signal transducer gp130 with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol Lett 31:123, 1992
91. Ip NY, Nye SH, Boulton TG, Davis S, Taga T, Li Y, Yasukawa K, Kishimoto T, Anderson DJ, Stahl N, Yancopoulos GD: CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 69:1121, 1992
92. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, Ziegler SF, Cosman D: The IL-6 signal transducer gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science 255:1434, 1992
93. Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, Klein B: Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 179:1337, 1994
94. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T: Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 179:1343, 1994
95. Paul SR, Barut BA, Bennett F, Cochran MA, Anderson KC: Lack of a role of interleukin-11 in the growth of multiple myeloma. Leuk Res 16:247, 1992
96. Lu ZY, Zhang XG, Gu ZJ, Yasukawa K, Etrillard M, Klein B: A highly sensitive quantitative biassay for human interleukin-11. J Immunol Methods 173:19, 1994
97. Nagata S, Tsuchiya M, Asano S, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H, Yamasaki T: The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J 5:575, 1986
98. Larsen A, Davis T, Curtis BM, Gimpel S, Sims JE, Cosman D, Park L, Sorensen E, March CJ, Smith CA: Expression cloning of human granulocyte colony-stimulating factor receptor: A structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med 72:1559, 1990
99. Ziegler SF, Bird TA, Morella KK, Mosley B, Gearing DP: Distinct regions of the human granulocyte colony stimulating factor receptor cytoplasmic domain are required for proliferation and gene induction. Mol Cell Biol 43:2384, 1993
100. Boiron JM, Portier M, Lu ZY, Bataille R, Klein B: G-CSF stimulates myeloma cell proliferation in vitro and in vivo through an IL-6 related mechanism. Blood 78:385a, 1991 (abstr, suppl 1)
101. Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Klein B: Cytokine gene expression in human multiple myeloma. Br J Haematol 85:514, 1993
102. Sawamura M, Sakura T, Miyawaki S: Exacerbation of monoclonal gammopathy in a patient treated with G-CSF. Ann Intern Med 118:318, 1993
103. Vora AJ, Hoc TC, Peel J, Greaves M: Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 86:180, 1994
104. de la Rubia J, Bonanad S, Palau J, Sanz GF, Sanz MA: Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant 14:475, 1994
105. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B: IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 147:4402, 1991
106. Brenning G: The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 35:178, 1985
107. Brenning G, Ahre A, Nilsson K: Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand J Haematol 35:543, 1985
108. Ludwig CU, Durie BGM, Salmon SE, Moon TE: Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 19:1625, 1983
109. Tanaka H, Tanabe O, Asaoku H, Ishikawa H, Nobuyoshi M, Kawano M, Kuramoto A: Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 74:1718, 1989
110. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, Dammaco F, Pileri A: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430, 1990
111. Peest D, Deicher H, Coldewey R: Melphalan and prednisone versus vincristine, BCNU, Adriamycin, melphalan, and dexamethasone induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German myeloma treatment group. Oncologie 13:458, 1990
112. Salmon SE, Crowley J: Evaluation of interferon on maintenance therapy for myeloma. Proceedings of the IV International Workshop on Multiple Myeloma, Mayo Clinic, Rochester, MN, October 2-5, 1993 (abstr)
113. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T: IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808, 1993
114. Bashey A, Healy L, Marshall CJ: Proliferative but not non-proliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the P21(Ras)/Map kinase signalling pathway. Blood 83:949, 1994
115. Neri A, Murphy JP, Cro L, Ferredo D, Tarella C, Baldini L, Dalla-Favera R: Ras oncogene mutation in multiple myeloma. J Exp Med 170:1715, 1989
116. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539, 1992
117. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S: Phosphorylation at Threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 90:2207, 1993
118. Rodriguez C, Theillet C, Portier M, Bataille R, Klein B: Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease. FEBS Lett 341:156, 1994
119. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M, Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. Blood 75:715, 1990
120. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B: Primary dexamethasone treatment of multiple myeloma. Blood 80:887, 1992
121. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC: 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89:883, 1992
122. Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B: Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine 5:578, 1993
123. Brakenhoff JPJ, de Hon FD, Fontaine V, Boekel ET, Schooltink H, Rose-John S, Heinrich PC, Content J, Aarden LA: Development of a human interleukin-6 receptor antagonist. J Biol Chem 269:86, 1994